Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi

Age

Volumn 36, Issue 2, 2014, Pages 613-623

  Du, Lai Ling ^a   Xie, Jia Zhao ^a   Cheng, Xiang Shu ^a   Li, Xiao Hong ^a   Kong, Fan Li ^a   Jiang, Xia ^a   Ma, Zhi Wei ^a   Wang, Jian Zhi ^a   Chen, Chen ^b   Zhou, Xin Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

ERK1 2; SIRT1; Streptozotocin; Tau phosphorylation

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RESVERATROL; SIRTUIN 1; STREPTOZOCIN; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVATION; ENZYME ACTIVITY; HIPPOCAMPUS; INSULIN RESISTANCE; MALE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SPATIAL MEMORY; TAU PROTEIN HYPERPHOSPHORYLATION;

AGING; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; CEREBRAL VENTRICLES; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FLUOROMETRY; HIPPOCAMPUS; INJECTIONS, INTRAPERITONEAL; MALE; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SIRTUIN 1; STILBENES; STREPTOZOCIN; TAU PROTEINS; VASODILATOR AGENTS;

EID: 84898873423     PISSN: 01619152     EISSN: 15744647     Source Type: Journal    
DOI: 10.1007/s11357-013-9592-1     Document Type: Article

References (52)

1. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB (2011) Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 71(3):365-376. doi: 10.1111/j.1365-2125.2010.03830.x
2. Araki T, Sasaki Y, Milbrandt J (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305(5686):1010-1013. doi: 10.1126/science.1098014
3. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61(5):661-666. doi: 10.1001/archneur.61.5.661
4. Baluchnejadmojarad T, Roghani M (2006) Effect of naringenin on intracerebroventricular streptozotocin-induced cognitive deficits in rat: a behavioral analysis. Pharmacology 78(4):193-197. doi: 10.1159/000096585
5. Banks AS, Kon N, Knight C, Matsumoto M, Gutierrez-Juarez R, Rossetti L, Gu W, Accili D (2008) SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8(4):333-341. doi: 10.1016/j.cmet.2008.08. 014
6. Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH (1996a) Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 45(9):1259-1266
7. Biessels GJ, Stevens EJ, Mahmood SJ, Gispen WH, Tomlinson DR (1996b) Insulin partially reverses deficits in peripheral nerve blood flow and conduction in experimental diabetes. J Neurol Sci 140(1-2):12-20
8. Braidy N, Jayasena T, Poljak A, Sachdev PS (2012) Sirtuins in cognitive ageing and Alzheimer's disease. Curr Opin Psychiatry 25(3):226-230. doi: 10.1097/YCO.0b013e32835112c1
9. Chandna S, Dwarakanath BS, Khaitan D, Mathew TL, Jain V (2002) Low-dose radiation hypersensitivity in human tumor cell lines: effects of cell-cell contact and nutritional deprivation. Radiat Res 157(5):516-525
10. Chu WZ, Qian CY (2005) Expressions of Abeta1-40, Abeta1-42, tau202, tau396 and tau404 after intracerebroventricular injection of streptozotocin in rats. Acad J First Med Coll PLA (Di 1 jun yi da xue xue bao) 25(2):168-170, 173
11. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, Lee VM (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2:252. doi: 10.1038/ncomms1255
12. Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX (2009) Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer's disease. Am J Pathol 175(5):2089-2098. doi: 10.2353/ajpath.2009. 090157
13. Donmez G, Wang D, Cohen DE, Guarente L (2010) SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 142(2):320-332. doi: 10.1016/j.cell.2010.06.020
14. Farrokhnia N, Roos MW, Terent A, Lennmyr F (2005) Experimental treatment for focal hyperglycemic ischemic brain injury in the rat. Exp Brain Res 167(2):310-314. doi: 10.1007/s00221-005-0157-0
15. Gagne J, Milot M, Gelinas S, Lahsaini A, Trudeau F, Martinoli MG, Massicotte G (1997) Binding properties of glutamate receptors in streptozotocin-induced diabetes in rats. Diabetes 46(5):841-846
16. Gardoni F, Kamal A, Bellone C, Biessels GJ, Ramakers GM, Cattabeni F, Gispent WH, Di Luca M (2002) Effects of streptozotocin-diabetes on the hippocampal NMDA receptor complex in rats. J Neurochem 80(3):438-447
17. Gillum MP, Erion DM, Shulman GI (2010) Sirtuin-1 regulation of mammalian metabolism. Trends Mol Med 17(1):8-13. doi: 10.1016/j.molmed.2010.09.005
18. Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101(3):757-770. doi: 10.1111/j.1471-4159.2006.04368.x
19. Guan QH, Pei DS, Zhang QG, Hao ZB, Xu TL, Zhang GY (2005) The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathways. Brain Res 1035(1):51-59. doi: 10.1016/j.brainres.2004. 11.050
20. He QP, Ding C, Li PA (2003) Effects of hyperglycemic and normoglycemic cerebral ischemia on phosphorylation of c-jun NH2-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK). Cell Mol Biol (Noisy-le-grand) 49(8):1241-1247
21. Hoyer S, Lannert H (2008) Long-term effects of corticosterone on behavior, oxidative and energy metabolism of parietotemporal cerebral cortex and hippocampus of rats: comparison to intracerebroventricular streptozotocin. J Neural Transm 115(9):1241-1249. doi: 10.1007/s00702-008-0079-7
22. Hoyer S, Lee SK, Loffler T, Schliebs R (2000) Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci 920:256-258
23. Hoyer S, Nitsch R (1989) Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transm 75(3):227-232
24. Julien C, Tremblay C, Emond V, Lebbadi M, Salem N Jr, Bennett DA, Calon F (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68(1):48-58. doi: 10.1097/NEN.0b013e3181922348
25. Kamal A, Biessels GJ, Gispen WH, Ramakers GM (2006) Synaptic transmission changes in the pyramidal cells of the hippocampus in streptozotocin-induced diabetes mellitus in rats. Brain Res 1073-1074:276-280. doi: 10.1016/j.brainres.2005.12.070
26. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26(13):3169-3179. doi: 10.1038/sj.emboj.7601758
27. Kurihara J, Katsura K, Siesjo BK, Wieloch T (2004) Hyperglycemia and hypercapnia differently affect post-ischemic changes in protein kinases and protein phosphorylation in the rat cingulate cortex. Brain Res 995(2):218-225
28. Li PA, He QP, Yi-Bing O, Hu BR, Siesjo BK (2001) Phosphorylation of extracellular signal-regulated kinase after transient cerebral ischemia in hyperglycemic rats. Neurobiol Dis 8(1):127-135. doi: 10.1006/nbdi.2000.0363
29. Li ZG, Zhang W, Sima AA (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56(7):1817-1824. doi: 10.2337/db07-0171
30. Liu WB, Li Y, Zhang L, Chen HG, Sun S, Liu JP, Liu Y, Li DW (2008) Differential expression of the catalytic subunits for PP-1 and PP-2A and the regulatory subunits for PP-2A in mouse eye. Mol Vis 14:762-773
31. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2011) Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 225(1):54-62. doi: 10.1002/path.2912
32. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450(7170):712-716. doi: 10.1038/nature06261
33. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D, Cole PA, Ott M, Gan L (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67(6):953-966. doi: 10.1016/j.neuron.2010.08.044
34. Namura S, Iihara K, Takami S, Nagata I, Kikuchi H, Matsushita K, Moskowitz MA, Bonventre JV, Alessandrini A (2001) Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A 98(20):11569-11574. doi: 10.1073/pnas.181213498
35. Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, Iqbal K, Grundke-Iqbal I (2002) Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res 109(1-2):45-55
36. Pei JJ, Gong CX, An WL, Winblad B, Cowburn RF, Grundke-Iqbal I, Iqbal K (2003) Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol 163(3):845-858. doi: 10.1016/S0002-9440(10)63445-1
37. Plaschke K, Kopitz J, Siegelin M, Schliebs R, Salkovic-Petrisic M, Riederer P, Hoyer S (2010) Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis 19(2):691-704. doi: 10.3233/JAD-2010-1270
38. Purushotham A, Xu Q, Li X (2012) Systemic SIRT1 insufficiency results in disruption of energy homeostasis and steroid hormone metabolism upon high-fat-diet feeding. FASEB J 26(2):656-667. doi: 10.1096/fj.11-195172
39. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiyagarajan M, MacGrogan D, Rodgers JT, Puigserver P, Sadoshima J, Deng H, Pedrini S, Gandy S, Sauve AA, Pasinetti GM (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281(31):21745-21754. doi: 10.1074/jbc.M602909200
40. Ramadori G, Fujikawa T, Anderson J, Berglund ED, Frazao R, Michan S, Vianna CR, Sinclair DA, Elias CF, Coppari R (2011) SIRT1 deacetylase in SF1 neurons protects against metabolic imbalance. Cell Metab 14(3):301-312. doi: 10.1016/j.cmet.2011.06.014
41. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434(7029):113-118. doi: 10.1038/nature03354
42. Roskoski R Jr (2012) ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res Off J Ital Pharmacol Soc 66(2):105-143. doi: 10.1016/j.phrs.2012.04.005
43. Salkovic-Petrisic M, Hoyer S (2007) Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl 72:217-233
44. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P (2006) Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem 96(4):1005-1015. doi: 10.1111/j.1471-4159.2005.03637.x
45. Sanz CM, Hanaire H, Vellas BJ, Sinclair AJ, Andrieu S, Group RFS (2012) Diabetes mellitus as a modulator of functional impairment and decline in Alzheimer's disease. The Real.FR cohort. Diabet Med 29(4):541-548. doi: 10.1111/j.1464-5491.2011.03445.x
46. Shonesy BC, Thiruchelvam K, Parameshwaran K, Rahman EA, Karuppagounder SS, Huggins KW, Pinkert CA, Amin R, Dhanasekaran M, Suppiramaniam V (2012) Central insulin resistance and synaptic dysfunction in intracerebroventricular- streptozotocin injected rodents. Neurobiol Aging 33(2):430. doi: 10.1016/j.neurobiolaging.2010.12.002, e435-418
47. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7(1):63-80
48. Stewart R, Liolitsa D (1999) Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 16(2):93-112
49. Takata H, Ikeda Y, Suehiro T, Ishibashi A, Inoue M, Kumon Y, Terada Y (2009) High glucose induces transactivation of the alpha2-HS glycoprotein gene through the ERK1/2 signaling pathway. J Atheroscler Thromb 16(4):448-456
50. Tjalve H, Castonguay A (1983) Distribution and metabolism in Syrian golden hamsters of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific carcinogen. Dev Toxicol Environ Sci 11:423-427
51. Visser D, van Zuylen GA, van Dam JC, Eman MR, Proll A, Ras C, Wu L, van Gulik WM, Heijnen JJ (2004) Analysis of in vivo kinetics of glycolysis in aerobic Saccharomyces cerevisiae by application of glucose and ethanol pulses. Biotechnol Bioeng 88(2):157-167. doi: 10.1002/bit.20235
52. Zhang JZ, Jing L, Ma AL, Wang F, Yu X, Wang YL (2006) Hyperglycemia increased brain ischemia injury through extracellular signal-regulated protein Kinase. Pathol Res Pract 202(1):31-36. doi: 10.1016/j.prp.2005.10.002